NEXTPro: Next Generation Radioligand Therapy for Prostate Cancer

Research unit

INNOSUISSE

Project number

134.816 IP-LS

Project title

NEXTPro: Next Generation Radioligand Therapy for Prostate Cancer

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Personalised medicine
Abstract (English)	NEXTPro develops a 177Lu-based radioligand therapy targeting prostatic acid phosphatase (PAP) for prostate cancer patients not responding to PSMA therapies. The project validates the lead candidate NEXTPro-131 through translational biodistribution, dosimetry, efficacy, and safety studies.